These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies. Chiriva-Internati M; Mirandola L; Kast WM; Jenkins MR; Cobos E; Cannon MJ Int Rev Immunol; 2011; 30(2-3):71-86. PubMed ID: 21557635 [TBL] [Abstract][Full Text] [Related]
8. Dendritic Cell Vaccines in Ovarian Cancer. Zhang X; He T; Li Y; Chen L; Liu H; Wu Y; Guo H Front Immunol; 2020; 11():613773. PubMed ID: 33584699 [TBL] [Abstract][Full Text] [Related]
9. Advanced clinical trials of dendritic cell vaccines in ovarian cancer. Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S J Investig Med; 2020 Oct; 68(7):1223-1227. PubMed ID: 32718940 [TBL] [Abstract][Full Text] [Related]
10. Dendritic cell-based vaccines: clinical applications in breast cancer. Gelao L; Criscitiello C; Esposito A; De Laurentiis M; Fumagalli L; Locatelli MA; Minchella I; Santangelo M; De Placido S; Goldhirsch A; Curigliano G Immunotherapy; 2014; 6(3):349-60. PubMed ID: 24762078 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of immunotherapy efficiency in mouse CaO-1 ovarian carcinoma treated by vaccines based on dendritic cells. Sitdikova SM; Kiselevskii MV; Sel'chuk VY; Amandzholov BS; Kurbatova EA; Donenko FV Bull Exp Biol Med; 2009 Feb; 147(2):226-8. PubMed ID: 19513427 [TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive factor blockade in dendritic cells via siRNAs results in objective clinical responses. Sioud M; Mobergslien A; Sæbøe-Larssen S Methods Mol Biol; 2015; 1218():269-76. PubMed ID: 25319657 [TBL] [Abstract][Full Text] [Related]
13. Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses. Homma S; Sagawa Y; Ito M; Ohno T; Toda G Clin Exp Immunol; 2006 Apr; 144(1):41-7. PubMed ID: 16542363 [TBL] [Abstract][Full Text] [Related]
15. Dendritic cell vaccines in melanoma: from promise to proof? Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431 [TBL] [Abstract][Full Text] [Related]
16. Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer. Chae CS; Teran-Cabanillas E; Cubillos-Ruiz JR Cancer Immunol Immunother; 2017 Aug; 66(8):969-977. PubMed ID: 28214928 [TBL] [Abstract][Full Text] [Related]
17. [Active cellular immunotherapy of ovarian cancer using dendritic cells]. Brtnicky T; Podrazil M; Bartunkova J; Spíšek R; Rob L Ceska Gynekol; 2012 Jun; 77(3):215-20. PubMed ID: 22779721 [TBL] [Abstract][Full Text] [Related]
18. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy. da Cunha A; Antoniazi Michelin M; Cândido Murta EF Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825 [TBL] [Abstract][Full Text] [Related]
20. Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care. Bapsy PP; Sharan B; Kumar C; Das RP; Rangarajan B; Jain M; Suresh Attili VS; Subramanian S; Aggarwal S; Srivastava M; Vaid A Cytotherapy; 2014 Feb; 16(2):234-44. PubMed ID: 24438902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]